South Korea · Delayed Price · Currency is KRW HEM Pharma Statistics
Total Valuation
HEM Pharma has a market cap or net worth of KRW 337.28 billion. The enterprise value is 344.53 billion.
| Market Cap | 337.28B |
| Enterprise Value | 344.53B |
Important Dates
The last earnings date was Thursday, June 11, 2026.
| Earnings Date | Jun 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HEM Pharma has 7.18 million shares outstanding. The number of shares has increased by 8.77% in one year.
| Current Share Class | 7.18M |
| Shares Outstanding | 7.18M |
| Shares Change (YoY) | +8.77% |
| Shares Change (QoQ) | +2.35% |
| Owned by Insiders (%) | 26.23% |
| Owned by Institutions (%) | 4.35% |
| Float | 4.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.40 |
| PB Ratio | 194.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.48, with a Debt / Equity ratio of 11.21.
| Current Ratio | 0.48 |
| Quick Ratio | 0.34 |
| Debt / Equity | 11.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.09 |
| Interest Coverage | -17.62 |
Financial Efficiency
Return on equity (ROE) is -194.38% and return on invested capital (ROIC) is -38.60%.
| Return on Equity (ROE) | -194.38% |
| Return on Assets (ROA) | -23.77% |
| Return on Invested Capital (ROIC) | -38.60% |
| Return on Capital Employed (ROCE) | -218.15% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.32 |
| Inventory Turnover | 12.82 |
Taxes
In the past 12 months, HEM Pharma has paid 3.66 million in taxes.
| Income Tax | 3.66M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +94.28% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +94.28% |
| 50-Day Moving Average | 59,174.00 |
| 200-Day Moving Average | 50,029.20 |
| Relative Strength Index (RSI) | 40.18 |
| Average Volume (20 Days) | 26,725 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HEM Pharma had revenue of KRW 14.41 billion and -25.61 billion in losses. Loss per share was -3,601.30.
| Revenue | 14.41B |
| Gross Profit | 267.64M |
| Operating Income | -17.06B |
| Pretax Income | -25.43B |
| Net Income | -25.61B |
| EBITDA | -14.37B |
| EBIT | -17.06B |
| Loss Per Share | -3,601.30 |
Balance Sheet
The company has 12.47 billion in cash and 19.43 billion in debt, with a net cash position of -6.96 billion or -970.47 per share.
| Cash & Cash Equivalents | 12.47B |
| Total Debt | 19.43B |
| Net Cash | -6.96B |
| Net Cash Per Share | -970.47 |
| Equity (Book Value) | 1.73B |
| Book Value Per Share | 199.50 |
| Working Capital | -23.20B |
Cash Flow
In the last 12 months, operating cash flow was -6.73 billion and capital expenditures -11.05 billion, giving a free cash flow of -17.79 billion.
| Operating Cash Flow | -6.73B |
| Capital Expenditures | -11.05B |
| Depreciation & Amortization | 2.70B |
| Net Borrowing | 17.86B |
| Free Cash Flow | -17.79B |
| FCF Per Share | -2,478.57 |
Margins
Gross margin is 1.86%, with operating and profit margins of -118.40% and -177.68%.
| Gross Margin | 1.86% |
| Operating Margin | -118.40% |
| Pretax Margin | -176.45% |
| Profit Margin | -177.68% |
| EBITDA Margin | -99.70% |
| EBIT Margin | -118.40% |
| FCF Margin | n/a |
Dividends & Yields
HEM Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.77% |
| Shareholder Yield | -8.77% |
| Earnings Yield | -7.59% |
| FCF Yield | -5.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HEM Pharma has an Altman Z-Score of -0.34 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.34 |
| Piotroski F-Score | 1 |